Want to see SE:BACTI.B full AI Analyst Report?
Bactiguard Holding AB (BACTI.B) AI Stock Analysis
Bactiguard Holding AB
(Nasdaq OMX AB:BACTI.B)
The overall score of 52 reflects a company in transition with significant risks. The primary positive driver is the improved financial health, specifically the strong recovery in cash flow and a more conservative balance sheet. However, this is heavily offset by a bearish technical trend and a critical deterioration in gross margins, which undermines the recent return to profitability. The negative P/E ratio further highlights the lack of sustainable earnings, making the stock a high-risk proposition despite its operational improvements.
Bactiguard Holding AB (BACTI.B) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 560.70M
- Dividend Yield
- ―
- Average Volume (3M)
- 6,645
- Price to Earnings (P/E)
- 88.9
- Beta (1Y)
- 0.33
- Revenue Growth
- -0.51%
- EPS Growth
- ―
- Country
- Sweden
- Employees
- 164
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Bactiguard Holding AB Business Overview & Revenue Model
Company Description
Bactiguard Holding AB (publ), a Swedish-based global medical technology company, specializes in developing and supplying innovative solutions designed to prevent infections. Its primary objective is to mitigate healthcare-associated infections (HAIs)...
How the Company Makes Money
Bactiguard makes money primarily through (1) licensing its infection-prevention coating technology to medical device manufacturers and (2) selling coated medical devices in certain product categories/markets, depending on how products are commerciali...
Bactiguard Holding AB Financial Statement Overview
Summary
Financial performance is mixed but improving. Cash flow is a clear strength (Score 70), with a robust recovery to positive free cash flow. The balance sheet is stable with decreasing leverage (Score 65). However, the income statement (Score 45) shows a critical risk: a return to profitability has come with a dramatic compression in gross margins, which questions the quality of earnings.
Income Statement
45NeutralBalance Sheet
65PositiveCash Flow
70Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 214.73M | 215.92M | 243.68M | 203.99M | 223.56M | 169.49M |
| Gross Profit | 145.46M | 184.65M | 207.71M | 139.98M | 180.14M | 130.80M |
| EBITDA | 48.72M | 45.15M | 24.99M | -89.98M | -543.00K | -5.94M |
| Net Income | 6.02M | -7.84M | -29.82M | -138.38M | -52.88M | -58.77M |
Balance Sheet | ||||||
| Total Assets | 524.24M | 545.06M | 655.91M | 662.17M | 807.70M | 849.29M |
| Cash, Cash Equivalents and Short-Term Investments | 55.05M | 44.26M | 116.73M | 123.22M | 197.73M | 217.59M |
| Total Debt | 153.75M | 162.92M | 227.77M | 233.10M | 238.70M | 247.96M |
| Total Liabilities | 210.91M | 230.13M | 327.57M | 309.00M | 311.99M | 307.84M |
| Stockholders Equity | 313.33M | 314.93M | 328.34M | 353.18M | 495.71M | 541.45M |
Cash Flow | ||||||
| Free Cash Flow | 27.59M | -7.21M | 10.21M | -60.94M | -7.86M | -38.00K |
| Operating Cash Flow | 30.38M | -1.49M | 24.99M | -52.33M | 3.06M | 7.26M |
| Investing Cash Flow | -2.79M | -5.72M | -14.78M | -8.61M | -10.92M | -7.29M |
| Financing Cash Flow | -13.31M | -62.74M | -21.20M | -11.84M | -13.89M | 205.83M |
Bactiguard Holding AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BACTI.B, the sentiment is Positive. The current price of 16.00 is above the 20-day moving average (MA) of 15.64, above the 50-day MA of 15.79, and below the 200-day MA of 16.20, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 52.63 is Neutral, neither overbought nor oversold. The STOCH value of 77.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:BACTI.B.
Bactiguard Holding AB Peers Comparison
Overall Rating
SE:GETI.B67Neutral
SE:SEZI57Neutral- SE:BACTI.B52Neutral
SE:INTEG.B50Neutral
SE:OSSD44Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SE:GETI.B | 67Neutral | SEK 75.64B | 26.73 | 9.13% | 1.71% | -3.90% | 37.73% |
| SE:SEZI | 57Neutral | SEK 532.17M | -5.46 | -35.44% | ― | 18.56% | 28.11% |
| SE:BACTI.B | 52Neutral | SEK 560.70M | 88.89 | 1.93% | ― | -0.51% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SE:INTEG.B | 50Neutral | SEK 243.48M | -5.77 | -20.71% | ― | 1.43% | 6.65% |
| SE:OSSD | 44Neutral | SEK 373.36M | -7.46 | ― | ― | -2.61% | -0.28% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:BACTI.B | Bactiguard Holding AB | 16.00 | -1.00 | -5.88% | |
| SE:GETI.B | Getinge AB (UK) | 277.70 | 60.83 | 28.05% | |
| SE:SEZI | Senzime AB | 3.38 | -2.45 | -41.94% | |
| SE:INTEG.B | Integrum AB Class B | 8.30 | 0.03 | 0.31% | |
| SE:PRO | Promimic AB | 9.45 | -4.55 | -32.50% | |
| SE:OSSD | OssDsign AB | 3.38 | -9.51 | -73.80% |
Bactiguard Holding AB Corporate Events
Bactiguard’s Partnership-Driven Growth Delivers Strong Q3 Turnaround
Bactiguard Holding AB reported a strong third quarter 2026, with total revenue rising 20.6% to SEK 58.4 million and net sales up 21.2% to SEK 55.1 million, driven mainly by its partnership model. Operating profit swung to SEK 6.8 million from a loss...
Bactiguard Sets Date for Q3 2026 Report and Investor Audiocast
Bactiguard Holding AB will publish its interim report for the third quarter of 2026 on 22 October at 07:00 CEST. The MedTech firm is organizing an audiocast and conference call the same day at 11:00 CEST, where CEO Christine Lind and CFO Patrick Bach...
Bactiguard Data Highlight Durable, Low-Silver Coating for Orthopedic Implants
Bactiguard has unveiled new data on its noble metal coating technology, reinforcing its distinct and durable performance on orthopedic implants. Presented at major international arthroplasty and infection conferences, the findings position the compan...
Bactiguard Adjusts Share Structure to Support 2026 Incentive Plan
Bactiguard Holding AB, a Stockholm-based MedTech firm listed on Nasdaq Stockholm’s Small Cap segment, develops noble metal coating technologies that prevent infections on medical devices and offers wound care products across orthopedics, cardio...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 24, 2026